|
|
 |
|
Viewing report
|
|
|
|
OTC Obesity in New Zealand
Euromonitor International, July 2010, Pages: 35
In 2009 OTC obesity only increased by less than 1% in current value terms; compared with 2008 this was a further slowdown. In current value terms sales reached NZ$2.0 million. Xenical by Roche Products New Zealand Ltd is still the only OTC obesity product available in the New Zealand market.
The OTC Obesity in New Zealand report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
- Get a detailed picture of the OTC Obesity market;
- Pinpoint growth sectors and identify factors driving change;
- Understand the competitive environment, the market’s major players and leading brands;
- Use five-year forecasts to assess how the market is predicted to develop.
|
|
|
|
